Alexandria Real Estate Equities is marking its 32nd year since founding as a garage startup and the creation of life science real estate as a dedicated asset class. Over three decades the company has delivered mission-critical infrastructure to address more than 90% of diseases that lack effective treatments, establishing itself as the preeminent owner, operator and developer of collaborative Megacampus™ ecosystems in major U.S. innovation clusters.

In its three largest markets—Greater Boston, the San Francisco Bay Area and San Diego—Alexandria generated 71% of annual rental revenue through September 30, 2025, with Megacampus occupancy at 91%, 18 percentage points above market averages. From January 1, 2023 through September 30, 2025, it leased 105% of the combined square footage leased by the next five largest life science landlords, and maintained an average tenant retention rate exceeding 80% over the past five years.

A flagship initiative for 2026 is Alexandria’s public-private collaboration with the Foundation for the National Institutes of Health on the MAP-D program, targeting major depressive disorder. This effort addresses a market of more than 21 million U.S. adults and an annual economic burden exceeding $380 billion. With the design phase complete, the clinical study to identify and validate biomarkers is set to launch in May, leveraging precision-medicine infrastructure on Alexandria’s campuses.

Rosen Law Firm has filed a securities class action on behalf of purchasers of Alexandria securities between January 27, 2025 and October 27, 2025, alleging materially false statements regarding revenue growth projections, funds-from-operations forecasts and the leasing value of its Long Island City property. Investors wishing to seek lead-plaintiff status must file with the court by January 26, 2026 to pursue claims of damages arising when the true condition of the LIC asset entered the market.